- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07448610
Hodnocení reálné bezpečnosti a účinnosti u pacientů s spinální svalovou atrofií léčených intratekálně onasemnogen abeparvovec-brve (OAV101B) (ITVISMA®): Pragmatická multicentrická studie v USA (STREAM)
Onasemnogene Abeparvovec: Hodnocení bezpečnosti a účinnosti v reálné klinické praxi u účastníků se spinální svalovou atrofií léčených intratekálním onasemnogenem abeparvovec-brve (ITVISMA®): Pragmatická multicentrická studie v USA (STREAM)
The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 4
Kontakty a umístění
Studijní kontakt
- Jméno: Novartis Pharmaceuticals
- Telefonní číslo: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Studijní záloha kontaktů
- Jméno: Novartis Pharmaceuticals
Studijní místa
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 208833
- Nábor
- Arkansas Children's Hospital
-
Vrchní vyšetřovatel:
- Aravindhan Veerapandiyan
-
Kontakt:
- Buffy Gofforth
- Telefonní číslo: (501) 364-1591
-
-
California
-
Stanford, California, Spojené státy, 94305-5235
- Nábor
- Stanford Hospital
-
Kontakt:
- Telefonní číslo: (650) 725-4341
- E-mail: NeuromuscularResearch@stanford.edu
-
Vrchní vyšetřovatel:
- John W Day
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Nábor
- Boston Childrens Hospital
-
Kontakt:
- Maggie Allen
- Telefonní číslo: (617) 919-3554
- E-mail: Maggie.Allen@childrens.harvard.edu
-
Vrchní vyšetřovatel:
- Leslie Hayes
-
-
New York
-
New York, New York, Spojené státy, 10032
- Nábor
- Columbia University Medical Center
-
Vrchní vyšetřovatel:
- Claudia Chiriboga
-
Kontakt:
- Kimberly Berry
- Telefonní číslo: 212-342-3038
- E-mail: kb2996@cumc.columbia.edu
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43210
- Nábor
- Ohio State University Medical Center
-
Vrchní vyšetřovatel:
- Bakri Elsheikh
-
Kontakt:
- Georgia (Gia) Cinkay
- Telefonní číslo: (614) 366-9050
- E-mail: Georgia.cinkay@osumc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 209277
- Nábor
- University of Pennsylvania
-
Vrchní vyšetřovatel:
- Lauren Elman
-
Kontakt:
- Amanda (Mandy) Hicks
- Telefonní číslo: (267) 496-3772
- E-mail: amanda.hicks@pennmedicine.upenn.edu
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Key Inclusion Criteria:
A participant will be enrolled in STREAM only if all the following conditions are met:
-
The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).
-
He or she is ≥ 2 years of age on the day of the intrathecal injection.
-
The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.
-
One of the following functional categories applies at screening:
- independently ambulatory child/adolescent 2 - <18 years; or
- independently ambulatory adult (≥ 18 years).
- non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
-
At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.
Key Exclusion Criteria:
A participant will be excluded if any of the following conditions apply:
- Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
- An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
- Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
- Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
- Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.
Other protocol inclusion, exclusion criteria may apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Onasemnogene Abeparvovec-brve
Participants with spinal muscular atrophy, including:
|
administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in HFMSE for independently ambulatory participants
Časové okno: Baseline, 6, 12, 18 and 24 months
|
The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression. The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
Časové okno: Baseline, 6, 12, 18 and 24 months
|
The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Časové okno: up to 5 years
|
Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs. |
up to 5 years
|
|
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
Časové okno: Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
|
Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. |
Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
|
|
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
Časové okno: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
Časové okno: Baseline, 6, 12, 18 and 24 months
|
Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Subgroup outcomes: Revised Upper Limb Module (RULM)
Časové okno: Baseline, 6, 12, 18 and 24 months
|
Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability. |
Baseline, 6, 12, 18 and 24 months
|
|
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Časové okno: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
Assessment of SMA-related healthcare-resource utilisation. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Časové okno: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
Assessment of SMA-related healthcare-resource utilisation. |
Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
|
|
Cobb angle
Časové okno: Baseline, up to 24 months
|
Assessment of scoliosis progression as a disease-progression marker. |
Baseline, up to 24 months
|
|
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
Časové okno: Baseline, up to 24 months
|
Assessment of respiratory function as a disease-progression marker. |
Baseline, up to 24 months
|
|
Joint-range limitation measured by goniometer
Časové okno: Baseline, up to 24 months
|
Assessment of evolution of joint contractures as a disease-progression marker. |
Baseline, up to 24 months
|
|
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
Časové okno: Baseline, up to 24 months
|
Assessment of nutrition status as a disease-progression marker. |
Baseline, up to 24 months
|
|
6-Minute Walk Test (6MWT) for ambulatory patients
Časové okno: Baseline, Months 6, 12, 18, and 24
|
To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity. |
Baseline, Months 6, 12, 18, and 24
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- COAV101B1US01
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .